Misuse of Drugs Act 1971 (Amendment) (No. 2) Order 2024

Baroness Doocey Excerpts

Tuesday 22nd October 2024 Grand Committee

[The Minister of State, Home Office (Lord Hanson of Flint) (Lab)]

My Lords, this order was laid before Parliament on 2 September. I thank the Advisory Council on the Misuse of Drugs, which I shall, for the purposes of brevity, call the ACMD from here on in, for its detailed and thorough advice, which has informed this draft order.

The purpose of this draft order is to amend Schedule 2 to the Misuse of Drugs Act, known as the MDA. The draft order will control six substances, as well as introduce a generic definition for nitazenes, as class A drugs and control 16 substances as class C drugs. The draft order will also make an amendment to an existing class B drug to give further clarity by adding an additional common name and its International Union of Pure and Applied Chemistry name to its entry.

I turn to 2-methyl-AP-237 and closely related substances. New synthetic opioids remain a current international and domestic public health threat. The ACMD has reported that, as with traditional opioids such as heroin, these can lead to dose-dependent adverse effects, including overdose risks, as well as the high potential for addiction and dependence. One of the 22 substances that I mentioned, 2-methyl-AP-237, was added to Schedule 1 to the Single Convention on Narcotic Drugs 1961 following the 66th session of the United Nations Commission on Narcotic Drugs. The UK is a signatory to that—I hope that Members have followed me so far—and we have an obligation to consider its introduction under domestic legislation.

On 27 March, the ACMD issued a report which considered the harms of 2-methyl-AP-237 but also provided advice to Ministers on closely related acyl piperazine opioids. The ACMD also noted the likelihood of further increases in their prevalence, as well as the potential health and social harms associated with specific acyl piperazine opioids. Following the recommendation from the ACMD, this draft order seeks to control four named acyl piperazine opioids and two chemically bridged acyl piperazine derivatives, which include 2-methyl-AP-237, as class A drugs under the MDA.

Under the MDA, there are several named nitazenes—another form of synthetic opioid—that are already listed as class A drugs. However, more needs to be done to reduce the opportunity for criminals to circumvent existing controls by making minor alterations to the chemical structure of these named drugs under control. As such, with this order we are trying to introduce a generic definition for nitazenes that has been recommended by the ACMD. The purpose of this is to future-proof the legislation by covering known and predicted variants likely to present a significant risk to health. The ACMD has already published four updates to address new structurally related compounds under the definition. As such, the draft order is designed to introduce a generic definition for nitazenes as a class A drug under the MDA.

I add for the Grand Committee’s consideration that many known benzodiazepines are used for medicinal purposes in the UK for the treatment of anxiety, insomnia and epilepsy, but more recently there has been an increase in the non-medical use of novel benzodiazepines and related compounds, which have been associated with significant health harms, including an increase in annual numbers of deaths where a benzodiazepine has been implicated.

The ACMD reported on benzodiazepines in 2020 but has since provided further advice on substances that are not controlled under the MDA. In the report dated March 2024—it obviously went to the previous Government—the ACMD recommended 15 benzo- diazepines for control, none of which is licensed as a medicine in the UK. As such, this draft order seeks to control those 15 benzodiazepines and related compounds as class C drugs under the MDA, in line with the ACMD’s advice.

We have seen an increase in the illicit use of xylazine, a non-opioid tranquiliser that has been approved for use in veterinary practice. Xylazine is being used to adulterate illicitly manufactured opioids, such as fentanyl, to produce a mixture known as “tranq” in the USA. In combination with other sedatives, it can dangerously lower a person’s level of consciousness. Again, these are recommendations to me, the ministry and the Home Office, and therefore, via the Home Office, to this House. The ACMD has recommended that the draft order should control xylazine as a class C drug under the MDA.

The order also looks at the entry for methoxphenidine, to add an additional common-use name and its full international standardised name, which will be covered by the order. This does not affect the existing control status of the substance as a class B drug. Instead, it will add clarity on exactly which drug is controlled, given that there are multiple common names.

I turn to the effect of this order. If it is made today, it will make the substances that I have indicated subject to controls under the MDA and associated offences. This will provide enforcement agencies, such as the police, with the appropriate powers to further restrict the supply and general use of the substances that I have mentioned. Unless exempt, these substances are likely also to be subject to the provisions of the Psychoactive Substances Act 2016, on which I fondly remember sitting in Committee in another place for many moons. Once controlled, they will be subject only to the provisions of the MDA and will no longer be covered by the Psychoactive Substances Act.

The MDA contains much higher penalties for the supply of these drugs and provides for a simple possession offence. Those who supply or produce class A drugs could face up to life imprisonment or an unlimited fine, or indeed both. For a class C drug, the penalty could be up to 14 years’ imprisonment or an unlimited fine, or both. Those found in unlawful possession face up to seven years in prison for a class A drug and up to two years in prison for a class C drug, or an unlimited fine, or indeed both.

Therefore, if this order is made, another statutory instrument will have to be introduced later, via the negative resolution procedure. This will seek to make amendments to the associated legislation, namely the Misuse of Drugs Regulations 2001 and, if necessary, the 2015 misuse of drugs designation order. This negative statutory instrument will seek to schedule and designate these substances to ensure that they are appropriately available for legitimate use, which is important for this House to know and consider.

Although all these substances, and the generic definition of nitazenes, have been identified as having no recognised medicinal use in the United Kingdom, xylazine remains a veterinary medicine. As such, this will be the only substance placed under Part 1 of Schedule 4 to the MDR, to enable its continued legitimate use. All others will be listed as Schedule 1 drugs and will require a Home Office-approved licence for research and other special purposes. It is the Government’s intention that these amendments will come into force on the same date as this affirmative order in due course early next year.

I hope that I have not surrounded noble Lords with too much information or too many acronyms, but it is important to note that this draft order encompasses a number of recommendations, all of which have been made by the ACMD following detailed and independent assessment of the harms associated with these substances. Noble Lords will know that drugs can ruin lives and continue to affect society as a whole. This Government are committed to protecting the public against such dangerous substances and ensuring that appropriate controls are in place. I hope that the Grand Committee will agree with the Home Office’s recommendations and this draft order. I beg to move.

[Baroness Doocey (LD)]

My Lords, we accept the recommendation of the advisory council and support the tightening of these regulations. I shall add a couple of comments. In relation to synthetic opioids, given the continual emergence of new individual nitazenes, we are in favour of introducing a generic control for these substances. They can be much more potent than heroin, leaving users at a particularly high risk of accidental overdose. Nitazenes have already cost lives in the UK, and although there is little local evidence of the impact of the other six synthetic opioids named in the order, the potential harm they could wreak is abundantly clear, given the high risk posed for addiction and fatality, as outlined by the Minister.

The need to keep up with organised crime’s ability to synthetise new varieties of opioid is crucial at a time when the UK and European markets are especially vulnerable to their influx, given the noted drop in the supply of heroin and fentanyl. The market is shifting as people seek alternatives, so it is highly likely that the substances named will become much more prevalent. The advisory council’s report calls the individual controlling of these six named synthetic opioids “a short-term approach”. Will the Government consult on the introduction of a generic definition for these substances similar to that for nitazenes?

I also have real concern about the UK’s ability to detect these new substances in a timely fashion. I note that screening and chemical testing for them is extremely limited, that many laboratories do not have the resources routinely to check for them and that they are often not incorporated into police drug tests. Given the damage that we have seen synthetic opioid addiction wreak on parts of the USA, it is of the utmost importance that we have all the warnings we can get of what is emerging on the UK market and where.

The importance of this is underlined by another of the substances we are dealing with today, xylazine. The first UK death in which it was implicated came to light only thanks to the vigilance of a toxicologist who detected it at postmortem because they decided to investigate what they thought were strange results. Internationally, heroin and synthetic opioids such as fentanyl are increasingly being cut with xylazine, and we know it is increasingly present in fatal overdoses in the US where in some states it is present in more than one-quarter of all drug deaths, yet because xylazine is not included in standard UK drug testing we do not know how widespread its use is here. It is a not a nice drug. It leaves people like zombies and its continued use rots their skin from the inside. Back in 2022, there was also apparently no way of recording it in the UK drug deaths database. Is this still the case? Will the Minister address my wider concerns around testing?

The Liberal Democrats do not believe that criminalising individuals for drug possession is the answer, and we will continue to call for a better public health response to tackling the drugs crisis. Will the Government make any additional funding available to enable the consistent national implementation of pre-arrest and pre-prosecution police drug diversion schemes?

[Lord Sharpe of Epsom (Con)]

My Lords, the Conservative Party welcomes this order. It controls six substances, introduces a generic definition for nitazenes as class A drugs and controls 16 substances as class C drugs. These Benches believe deeply in the principles of law and order, personal responsibility and the protection of our communities. This amendment embodies those very principles by addressing the evolving nature of the drugs trade and reinforcing our nation’s commitment to keeping our streets safe.

In May, the previous Conservative Government accepted all five recommendations set out in the Advisory Council on the Misuse of Drugs’ March 2024 report. I welcome the new Government’s continuation of our excellent work. These regulations will build on the previous Government’s work to mitigate the real threat of synthetic opioids across the UK by banning 15 new synthetic opioid drugs.